Breaking Finance News

Royal Bank Of Canada announced K2M Group Holdings Inc (NASDAQ:KTWO), bumping up its stock price target to $23.00 today

In a report released on 10/10/2016 Royal Bank Of Canada increased the stock price target of K2M Group Holdings Inc (NASDAQ:KTWO) to $23.00 reporting a possible upside of 0.25%.

Previously on 10/5/2016, Zacks Investment Research reported on K2M Group Holdings Inc (NASDAQ:KTWO) increased the target price from $0.00 to $20.00. At the time, this indicated a possible upside of 0.11%.

Just yesterday K2M Group Holdings Inc (NASDAQ:KTWO) traded 1.38% higher at $18.40. K2M Group Holdings Inc’s 50-day moving average is $16.94 and its 200-day moving average is $15.45. The last closing price is up 19.10% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 150,070 shares of KTWO traded hands, down from an average trading volume of 275,085

Recent Performance Chart

K2M Group Holdings Inc (NASDAQ:KTWO)

K2M Group Holdings Inc has 52 week low of $10.10 and a 52 week high of $21.67 and has a market capitalization of $0.

In addition to Royal Bank Of Canada reporting its target price, a total of 7 firms have reported on the stock. The consensus target price is $20.43 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally zero equity analysts rating the company a sell.

More About K2M Group Holdings Inc (NASDAQ:KTWO)

K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company's spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company's product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries. The Company's technologies include MESA, Rail 4D, Quicket Deformity, CAPRI, SERENGETI, RAVINE, EVEREST, CASCADIA and tifix.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *